Clinical trial NCT06604624: Semaglutide in Treatment of Obesity
Official title: To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Weight Management
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-09-19
Enrollment: 462
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years old (at the time of signing ICF), both male and female;
2. BMI≥28 kg/m\^2 during screening;
3. Within 90 days before screening, the weight change range controlled by diet and exercise alone is less than 5% (see section 1.3 for the calculation formula);
4. Voluntarily participate in the trial and sign the informed consent.

Exclusion Criteria:

1. Meet any of the following requirements: (1) HbA1c≥6.5% or fasting venous blood glucose ≥7.0 mmol/L during screening; (2) a history of type 1 or type 2 or a specific type of diabetes;
2. Obesity is caused by drugs or diseases (e.g. Cushing\&amp;#39;s syndrome, acromegaly, etc.); or weight gain caused by increased non-fat content (e.g. edema);
3. Received (including) drug therapy with GLP-1 receptor agonists (single target, double target, or multiple target) within 90 days prior to screening;
4. Received any other drug or product or treatment within 90 days prior to screening that the investigator determines will affect the assessment of weight efficacy of the trial, including but not limited to drugs or products or treatments that contain overweight/obesity or equivalent meaning in the label indications, hypoglycemic drugs, tricyclic antidepressants, antipsychotic or antiepileptic drugs (such as sodium valproate, citalopram, etc.), systemic use of glucocorticoids, etc.;
5. Previous bariatric metabolic surgery (except for previous liposuction, abdominal plastic surgery, intragastric balloon extraction or duodenal jejunal cannulation extraction \&amp;gt; 1 year), or planned to receive any surgical treatment during the trial that might affect the evaluation of weight efficacy;
6. Past allergy or suspected allergy to GLP-1 receptor agonists, or past allergy to investigational drug ingredients;
7. Participated in any other trial and received at least one treatment in the 90 days prior to screening;
8. Thyroid function is unstable or uncontrolled 90 days before screening, or TSH\&amp;gt; 6.0 mIU/L or \&amp;lt; 0.4 mIU/L at screening;
9. Previous or family history of medullary thyroid carcinoma or multiple endocrine adenomatosis type 2 (MEN-2) before screening;
10. Diagnosis of malignant tumors within 5 years prior to screening (except cured skin basal cell carcinoma or cervical carcinoma in situ);
11. Have any of the following major cardiovascular and cerebrovascular history in the 180 days prior to screening: history of myocardial infarction, coronary angioplasty or bypass surgery, valvular heart disease or heart valve repair, clinically significant and treatment-requiring arrhythmia, unstable angina pectoris, decompensated cardiac insufficiency (NYHA Class III or IV), transient ischemic attack, cerebrovascular accident, etc.;
12. Serious gastrointestinal disease (e.g. abnormal gastric emptying, inflammatory bowel disease) before or during screening;
13. Patients with moderate to severe depression at the time of screening, or the total score of PHQ-9 at the time of screening ≥15 points; or history of other serious mental illness (e.g., schizophrenia, bipolar disorder); or have a history of suicidal thoughts, attempted suicide or suicidal behavior;
14. The presence of any of the following before or during screening: chronic pancreatitis, acute pancreatitis, symptomatic gallbladder disease (except cholecystectomy);
15. Any of the following items should be met during screening: (1) systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; (2) QTcF interval of ECG \&amp;gt;450 ms for male or \&amp;gt;470 ms for female; (3) eGFR\&amp;lt; 30 mL/min/1.73 m\^2, eGFR is calculated according to CKD-EPI formula; (4) ALT or AST \&amp;gt; 3× upper limit of normal value; (5) blood amylase or blood lipase \&amp;gt; 1.5× the upper limit of normal value; (6) blood triglyceride \&amp;gt; 5.7 mmol/L; (7) calcitonin ≥50ng/L (pg/mL); (8) HIV antibody or HCV antibody or HBsAg positive (except for HBsAg positive but HBV DNA quantitative test results are not higher than the upper limit of the test reference range and no anti-HBV drugs are used during screening);
16. A history of drug abuse, drug use or alcohol dependence;
17. Total blood donation ≥400 mL or one-time blood loss ≥400 mL within 90 days before screening;
18. Fertile female subjects are pregnant or lactating at the time of screening, or had positive HCG blood; or fertile male or female subjects and their partners are unable to use effective contraception during the trial period and within 3 months after the end of treatment;
19. Other situations in which the investigator does not consider participation in the study appropriate.

Primary outcomes:
measure: Relative percentage change in body weight from baseline at 44 weeks of treatment
timeFrame: Baseline through Week44
Secondary outcomes:
measure: Proportion of subjects with a weight loss of ≥5% from baseline at 44 weeks of treatment
timeFrame: Baseline through Week44
measure: Proportion of subjects with a weight loss of ≥10% from baseline at 44 weeks of treatment
timeFrame: Baseline through Week44
measure: Changes in waist circumference from baseline at 44 weeks of treatment
timeFrame: Baseline through Week44
measure: Number of TEAE and SAE cases during the experiment
timeFrame: Week0 through Week44
measure: Changes in pulse from baseline at 44 weeks of treatment
timeFrame: Baseline through Week44
measure: Anti-drug antibodies, neutralizing antibodies (anti-drug antibody positive)
timeFrame: Baseline through Week44
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
Study officials:
References: